Detalhe da pesquisa
1.
Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial.
Diabetes Obes Metab
; 25(5): 1261-1270, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635232
2.
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Diabetes Obes Metab
; 24(1): 61-71, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514692
3.
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Circulation
; 141(17): 1360-1370, 2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32098501
4.
Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
Diabet Med
; 38(10): e14552, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33690915
5.
Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
Diabetes Obes Metab
; 23(7): 1496-1504, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33620762
6.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies.
Diabetes Obes Metab
; 23(2): 549-560, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145944
7.
Measuring Software Maintainability with Naïve Bayes Classifier.
Entropy (Basel)
; 23(2)2021 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33499278
8.
Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Circulation
; 140(20): 1613-1622, 2019 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31542942
9.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(13): 1228-1239, 2017 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28910237
10.
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Diabetes Obes Metab
; 22(9): 1516-1526, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311204
11.
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT-1 and -2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2.
Diabetes Obes Metab
; 22(11): 2151-2160, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32691513
12.
The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer.
J Surg Oncol
; 122(2): 144-154, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346902
13.
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Diabetes Obes Metab
; 21(4): 883-892, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30499237
14.
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(1): 165-172, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685973
15.
Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes.
Diabetes Obes Metab
; 20(2): 463-467, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28857388
16.
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
Diabetes Obes Metab
; 20(6): 1542-1546, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29446523
17.
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Am Heart J
; 187: 1-9, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28454792
18.
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Cardiovasc Diabetol
; 16(1): 113, 2017 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28903775
19.
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Diabetes Obes Metab
; 19(7): 979-988, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28205322
20.
Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study.
Diabetes Obes Metab
; 19(7): 1045-1050, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28181728